Skip to main content
padlock icon - secure page this page is secure

Free Content Risk factors for unfavourable treatment outcomes among rifampicin-resistant tuberculosis patients in Tajikistan

Download Article:
(PDF 90.5 kb)
SETTING: Tajikistan is among the 30 countries with the highest multidrug-resistant tuberculosis (MDR-TB) burden.

OBJECTIVE: To investigate the risk factors for unfavourable treatment outcomes among rifampicin-resistant (RR)/MDR-TB patients.

DESIGN: Retrospective medical chart review of RR/MDR-TB patients enrolled for treatment in 2012–2013.

RESULTS: Of 601 RR/MDR-TB patients, 58 (9.7%) had pre-extensively drug-resistant TB (pre-XDR-TB; i.e., MDR-TB with additional resistance to a fluoroquinolone or second-line injectable agent) and 45 (8%) had XDR-TB (MDR-TB with additional resistance to both). Treatment failure and death were reported in respectively 40 (7%) and 89 (15%) cases; 60 (10%) patients were lost to follow-up (LTFU). In multivariable analysis, treatment failure was associated with pre-XDR-TB (adjusted odds ratio [aOR] 3.67, 95%CI 1.47–9.18) or XDR-TB (aOR 8.61, 95%CI 3.48–21.34). Death was associated with age >45 years vs. <25 years (aOR 3.47, 95%CI 1.68–7.19) and no record of any adverse event during treatment (aOR 2.55, 95%CI 1.48–4.39). Changing place of residence during treatment was an independent predictor of LTFU (aOR 4.61, 95%CI 2.41–8.8).

CONCLUSIONS: Our findings highlight the need for 1) the use of regimens with new anti-tuberculosis drugs; 2) good handover of TB patients and 3) effective tracing mechanisms if patients change a place of residence to prevent LTFU.
No Reference information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Keywords: adverse event; loss to follow-up; retrospective cohort study; second-line anti-tuberculosis drug; treatment failure

Document Type: Research Article

Affiliations: 1: KNCV Tuberculosis Foundation, Country Office, Dushanbe 2: USAID TB Control Project, Dushanbe 3: National Centre of Population Protection from Tuberculosis, Dushanbe, Tajikistan 4: Technical Division, Team Evidence, KNCV Tuberculosis Foundation, The Hague, The Netherlands 5: Technical Division, Team Evidence, KNCV Tuberculosis Foundation, The Hague, The Netherlands, Department of Public Health, Epidemiology, and Biostatistics, David Tvildiani Medical University, Tbilisi, Georgia

Publication date: March 1, 2019

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease (IJTLD) is for clinical research and epidemiological studies on lung health, including articles on TB, TB-HIV and respiratory diseases such as COVID-19, asthma, COPD, child lung health and the hazards of tobacco and air pollution. Individuals and institutes can subscribe to the IJTLD online or in print – simply email us at [email protected] for details.

    The IJTLD is dedicated to understanding lung disease and to the dissemination of knowledge leading to better lung health. To allow us to share scientific research as rapidly as possible, the IJTLD is fast-tracking the publication of certain articles as preprints prior to their publication. Read fast-track articles.

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more